Core Viewpoint - Kangji Medical has completed its privatization with a valuation of $1.4 billion, marking its exit from the capital market after five years of listing on the Hong Kong Stock Exchange [2] Group 1: Privatization Process - The privatization process began on July 17, 2025, when Knight Bidco Limited requested the board to present a privatization proposal to shareholders [3] - The privatization offer was officially announced on August 12, 2025, with shareholders set to receive HKD 9.25 per share, representing a 21.7% premium over the closing price on June 30, 2025 [4] - The proposal received shareholder approval on November 10, 2025, leading to the final trading of Kangji Medical shares on December 9, 2025 [4] Group 2: Financial Performance and Market Context - Kangji Medical's stock price fell over 64% from its initial listing price of HKD 23.679 to HKD 8.42 by the time of the privatization announcement [3] - The company reported revenue of CNY 497 million for the six months ending June 30, 2025, an increase of 8.3%, but net profit attributable to shareholders decreased by 7% to CNY 266 million, indicating challenges in profitability despite revenue growth [7] - The privatization reflects broader valuation challenges in the Hong Kong medical sector, with other companies like China Traditional Chinese Medicine and Sai Sheng Pharmaceutical also pursuing privatization due to similar pressures [8] Group 3: Strategic Considerations - The decision for privatization was influenced by factors such as limited equity financing capabilities, long-term stock price underperformance, and the need to reduce compliance costs [3][6] - Kangji Medical aims to focus on long-term strategic decisions, including R&D investments and operational upgrades, which are hindered by short-term performance pressures in a competitive market [6][7] - The involvement of major investors like TPG and Qatar Investment Authority, who collectively hold 74.75% of the company, provides a solid foundation for the privatization process [5]
溢价9.9％“上岸”？吻合器龙头康基医疗港股退市，医疗板块估值困局再添注脚